Skip to main content

Table 3 Trend test and dose-dependent effect of the intensity of PPAR-γ modulating treatments on risk of recurrent ischemic stroke by using the whole cohort before matching

From: Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study

TrendPatient numberNo. of event (%)p trendp trend
Trend test of telmisartan and pioglitazone effect0.0870.076
 Pioglitazone plus telmisartan24642 (17.1)  
 Pioglitazone alone2944556 (18.9)  
 Telmisartan alone2259490 (21.7)  
Dose-dependent effect of pioglitazone0.0150.068
 MPR ≥ 801406231 (16.4)  
 MPR < 801784367 (20.6)  
 Non-pioglitazone32,6456973 (21.4)  
  1. PPAR-γ peroxisome proliferator-activated receptor-gamma, MPR medication possession ratio
  2. Statistical significance was set at p < 0.05
  3. Adjusted for all the variables listed in Table 1, except medications, follow-up years and the propensity score